Mr G Teeling-Smith (Office ofHealth Economics, London) Advertising and the Pattern of Prescribing I would like to associate myself with two points which have emerged from the previous papers. The first is that, as Dr Paget has implied, innovation must be considered as a total concept. Many of Britain's present economic problems arise from the mistaken idea that research and development in isolation have an intrinsic value. In economic terms this is not true; they are only of value if they lead to new products or methods being used in practice. This means that they must be developed commercially as well as scientifically; they must also be marketed. The total process of innovation, therefore, consists of an indivisible trio of research, development and marketing. It is utterly illogical to deify technology and at the same time to denigrate advertising. Yet this is just what some exceedingly prominent politicians have been doing in the past. The only legitimate grounds for criticism would be an imbalance between the three stages of research, development and marketing, and I do not think that anyone yet knows enough about the economics of the subject to say what the correct balance should be.
Secondly, I want to endorse Mr McLeod's comments about the importance of avoiding misleading advertising. In this connexion, anyone concerned with marketing in the pharmaceutical industry, or any professional advertising man associated with it, should not only be aware of, but should be familiar in detail with, the Association of the British Pharmaceutical Industry's Code of Practice to which he referred. The third edition of this Code which has just been published is even more specific and more stringent than before. If anyone feels that claims are unjustified, or that too little is made of a product's side-effects or contra-indications, they should ask for the advertisement in question to be put before the ABPI Code of Practice Committee which now meets under the Chairmanship of Sir Joseph Molony QC, formerly Chairman of the Committee on Consumer Protection. Also under this Code, if some doctors still think that pharmaceutical advertising as a whole is a waste of time, they need only tell the ABPI that they wish to receive none of it.
From these two points, it appears that advertising is an economic necessity for any researchbased industry and that in the case of medicines efficient machinery now exists to control its content.
The role and influence of advertising in individual doctors' prescribing decisions is an extraordinarily complex subject over which, once again, there has been some confusion. Doctors themselves have sometimes come to doubt the logic of their own actions; some general practitioners have even expressed the view that their prescribing would be improvedor certainly that of their colleagues could be improved! -if there were stronger authoritarian direction over which products should be prescribed and which should not. They have suggested that the present pattern of competitive advertising, the hurly-burly of the market place as it were, is inimical to the scientific practice of medicine. I believe this is quite untrue and would like to suggest why. Much of what I am going to say is still hypothesis rather than proven fact, but we are at present undertaking and sponsoring research to test our beliefs. My argument has also necessarily been contracted and simplified to fit it into the time available.
First, there is substantial evidence that doctors reach their prescribing decisions on the basis of information from many different sources, including the pharmaceutical industry's advertising. Depending on the type of product involved, this advertising plays a greater or lesser role both in informing doctors about the existence of products and in convincing them to prescribe. Secondly, market research data, and other prescribing records, show that individual doctors reach very different prescribing decisions. This must be because, as individuals, they are naturally influenced in different ways, both because they choose to select different parts of the total information available to them, and because that which they do select will have a different impact on different listeners or readers, depending on factors such as their age and training and the nature of their practice.
There is also some evidence to suggest that individual doctors have fairly set patterns of prescribing with a comparatively small number of preparations on which they normally rely. Although there are many different antibiotics, antidepressives and antacids, for example, an individual doctor will normally prescribe the same one or two each time as an initial treatment. It is only when one of these tried favourites fails for a particular patient that he will go outside his established pattern of prescribing. This pattern of prescribing has been acquired as a result of many influences including that of company advertising. Thus doctors each have very different patterns of prescribing, but for each individual the pattern Library (Scientific Research) Section is probably fairly static. It is our hypothesis that this situation arises in the following way. For any particular disease or condition a wide spectrum of treatments is available; some are many years old and now perhaps discredited; some are major therapeutic landmarks typically introduced at intervals in the past thirty years; others are variants on each of these landmarks and may be greater or lesser improvements on the original, perhaps of benefit to only a minority of patients. Each product will differ from the others multifactorially; that is they cannot be rated against each other on a single scale. Their differences will include efficacy, toxicity, side-effects, convenience and price. For the first three of these, and possibly the fourth also, the comparative ranking of different preparations may vary substantially from patient to patient. A product which is good and safe for one patient may be toxic and ineffective for another. All this is commonplace but is often forgotten when an individual's pattern of prescribing is being considered. The last and most important factor is that, other things being equal, a doctor will be very much more effective when prescribing a preparation with which he is familiar than one which is strange to him. At any one time, several out of the total range of treatments will be advertised, and they may also be referred to in journals or by local consultants, for example. This will only influence a doctor to prescribe if he is convinced that the product offers a substantial advantage over a more familiar one. This will depend to some extent on the ease with which the doctor is influenced, but also significantly on which treatment he would otherwise have used. Some will always prefer the latest available treatment, but even so they would probably not switch for a trivial advantage. Most doctors probably prefer to wait until a product has been in use for some time before they are prepared to adopt it; but in their routine prescribing they too will only replace one established product by another if they are convinced of its significant advantage. Superimposed on this process by which doctors' regular prescribing habits are formed there are also the exceptional situations when the doctor's tried favourite has failed for a particular patient.
He then has to fall back on the alternatives available. Once again he will learn about these either from advertising or from other sources. If a product used under these circumstances is notably successful, the doctor may adopt it for routine use in future.
The effect of this process is to create the situation in which individual doctors are, as it were, out of step with their colleagues in their prescribing. Some will just have adopted the very latest advance; some will recently have adopted a new product introduced perhaps five years ago; some will still be prescribing the five-year-old product having adopted it when it was first introduced; some will still be using a more traditional remedy but may be on the brink of moving forward. In each case the doctor will be prepared to go on to an alternative if his normal prescription fails. Those who are most advanced in one therapeutic area may be well behind in another; a few years later this pattern may be reversed. Although it may sound haphazard, this is just as logical a pattern of prescribing as any which could be dictated by a central advisory body whose opinion must be based on the average performance of different medicines. It has the overwhelming advantage that it allows experience to be gained by at least some doctors with each new product. It is on this experience that further innovation can be based, and on which eventual judgments on relative efficacy can be made. The sales revenue from each new product also provides the commercial support for further innovation.
Finally, it means that many alternative treatments are available for the patient who does not respond satisfactorily to the first or second choice. This process is stimulated by the progressive pressure of advertising. Against this, there is counter-pressure from those who question the value of, or necessity for, almost every new product put on the market. Their resistance to changeconservatismis a useful force. However, there are many historical examples to show how inherent resistance to change has inhibited progress; it needs a strong forward pressure, such as that of advertising, to overcome it. Without advertising, a product which appears on introduction to be only a minor advance has a negligible chance of success. And many very widely prescribed products now in the pharmacopeeia were in fact introduced, fortunately with advertising, in exactly this situation. In these cases the faith of the innovators in their new product has proved more justified than the scepticism expressed by the medical establishment. As an aside, I should point out that this phenomenon is by no means confined to medicine. The Church reacted in the same way to Galileo and his ideas. The Luddites did it with mechanization. The Consumers' Association persistently questions the price and value of technical innovations.
The particular significance of commercial competitive advertising is that it alone can create the step by step forward pattern. Articles in journals and discussions between doctors are not sufficient to ensure that new products are tried. The alternative is to await a central decision that a particular new product is a major advance for the majority of patients. Although this may sound theoretically attractive it would inevitably delay progress and deprive a minority of patients of alternatives which might be significantly better for them. This is not mere free-enterprise dogma. Precisely this situation has arisen with the Medresco hearing aids. Commercial hearing aids have become steadily more attractive, and the variety of models available provide relief for almost all the deaf. The standard Medresco models have continued to be issued long after at least their external design is obsolete; a minority of deaf cannot benefit from the standard models available. This problem is recognized and is being actively tackled by the Ministry of Health. Without advertising it could have arisen with NHS medicines also.
In conclusion, in this brief paper I have been putting a straightforward case on the contribution of advertising to pharmaceutical progress. In general, the conventional case against advertising is that it misleads a gullible public, it misdirects private spending to frivolous objectives and it wastes money. In medicine, misleading advertis-ing should be prevented by the measures I have mentioned. The machinery for control exists, and those who think that abuses still occur should use that machinery rather than make criticisms elsewhere. I hope I have also shown that pharmaceutical advertising produces a pattern of prescribing which has advantages over that which would result from purely noncommercial advice on prescribing. Certainly I believe that it has contributed to pharmaceutical progress to a no less significant extent than research and development itself. If this is so, the cost of advertising must be looked at in a very different light from that of the past. None of this, of course, means that everything is satisfactory. What we need is more concentration on therapeutics and pharmacology in medical education and in postgraduate education particularly. This would help the patterns of prescribing to progress forward more smoothly than at present. It would also help to redistribute the responsibility for progress between advertising where it lies mainly at present, and teaching, where much of it should lie. I think that a positive approach of this sort, improving the continuing training which doctors receive in pharmacology, would be very much more effective in raising our standards of prescribing than further controls on advertising.
